Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (12), 3462-71

Management of Hepatocellular Carcinoma With Portal Vein Thrombosis

Affiliations
Review

Management of Hepatocellular Carcinoma With Portal Vein Thrombosis

Matthew Quirk et al. World J Gastroenterol.

Abstract

Management of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) is complex and requires an understanding of multiple therapeutic options. PVT is present in 10%-40% of HCC at the time of diagnosis, and is an adverse prognostic factor. Management options are limited, as transplantation is generally contraindicated, and surgical resection is only rarely performed in select centers. Systemic medical therapy with sorafenib has been shown to modestly prolong survival. Transarterial chemoembolization has been performed in select cases but has shown a high incidence of complications. Emerging data on treatment of PVT with Y-90 radioembolization suggest that this modality is well-tolerated and associated with favorable overall survival. Current society guidelines do not yet specifically recommend radioembolization for patients with PVT, but this may change with the development of newer staging systems and treatment algorithms. In this comprehensive literature review, we present current and available management options with the relative advantages, disadvantages and contraindications of these treatment options with summarized data on overall survival.

Keywords: Hepatocellular carcinoma; Management; Portal vein thrombosis; Selective internal radiation therapy; Yttrium 90.

Similar articles

See all similar articles

Cited by 30 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback